ARCHIVED: Mastectomy plus reconstruction has highest rate of complication, complication-related costs of guideline-concordant therapies for early breast cancer
In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age. It was also the most expensive treatment option in a younger patient population, according to a new study from Â鶹ӳ» MD Anderson Cancer Center.?
The research is published in the Journal of the...
ARCHIVED: MD Anderson Cancer Center and Adaptimmune form strategic alliance to advance development of immunotherapies targeting multiple cancers
Adaptimmune Therapeutics and Â鶹ӳ» MD Anderson Cancer Center announced today they have entered into a multi-year strategic...
ARCHIVED: Melanoma tumors use interferon-gamma mutations to fight immunotherapy
Melanoma tumors use genetic mutations in a prominent immune response pathway to resist the immunotherapy ipilimumab, researchers from The...
ARCHIVED: Rogers Award for Excellence in Prevention awarded to Maher Karam-Hage, M.D.
Maher Karam-Hage, M.D., professor, Behavioral Science and Psychiatry, and associate medical director, Tobacco Treatment Program, is the 2016 recipient of the Julie and Ben Rogers Award for Excellence in Prevention at Â鶹ӳ» MD Anderson Cancer Center.
The annual award, now in its 30th year, recognizes employees who consistently demonstrate excellence in their work and dedication to MD?Anderson¡¯s mission to...
ARCHIVED: MD Anderson and Rice University welcome Vice President Biden to Houston for 54th Anniversary of President Kennedy Moonshot Speech
Â鶹ӳ» MD Anderson Cancer Center is pleased to welcome Vice President Joe Biden to Houston and the historic site where 54...
ARCHIVED: MD Anderson receives $19 million in CPRIT funding for recruitment and research
Â鶹ӳ» MD Anderson Cancer Center was awarded $19 million this week from the Cancer Prevention and Research Institute of Texas...
ARCHIVED: Combination therapy shows promise for chronic myeloid leukemia
A study in mice combining two inhibitor drugs for treatment of chronic myeloid leukemia (CML) has revealed potential for not only stopping...